Back to Search
Start Over
Identification of potential biomarkers and candidate small molecule drugs in glioblastoma
- Source :
- Cancer Cell International, Vol 20, Iss 1, Pp 1-14 (2020), Cancer Cell International
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- Background and aims Glioblastoma (GBM) is a common and aggressive primary brain tumor, and the prognosis for GBM patients remains poor. This study aimed to identify the key genes associated with the development of GBM and provide new diagnostic and therapies for GBM. Methods Three microarray datasets (GSE111260, GSE103227, and GSE104267) were selected from Gene Expression Omnibus (GEO) database for integrated analysis. The differential expressed genes (DEGs) between GBM and normal tissues were identified. Then, prognosis-related DEGs were screened by survival analysis, followed by functional enrichment analysis. The protein–protein interaction (PPI) network was constructed to explore the hub genes associated with GBM. The mRNA and protein expression levels of hub genes were respectively validated in silico using The Cancer Genome Atlas (TCGA) and Human Protein Atlas (HPA) databases. Subsequently, the small molecule drugs of GBM were predicted by using Connectivity Map (CMAP) database. Results A total of 78 prognosis-related DEGs were identified, of which10 hub genes with higher degree were obtained by PPI analysis. The mRNA expression and protein expression levels of CETN2, MKI67, ARL13B, and SETDB1 were overexpressed in GBM tissues, while the expression levels of CALN1, ELAVL3, ADCY3, SYN2, SLC12A5, and SOD1 were down-regulated in GBM tissues. Additionally, these genes were significantly associated with the prognosis of GBM. We eventually predicted the 10 most vital small molecule drugs, which potentially imitate or reverse GBM carcinogenic status. Cycloserine and 11-deoxy-16,16-dimethylprostaglandin E2 might be considered as potential therapeutic drugs of GBM. Conclusions Our study provided 10 key genes for diagnosis, prognosis, and therapy for GBM. These findings might contribute to a better comprehension of molecular mechanisms of GBM development, and provide new perspective for further GBM research. However, specific regulatory mechanism of these genes needed further elaboration.
- Subjects :
- Cancer Research
Microarray
In silico
Brain tumor
Human Protein Atlas
Biology
urologic and male genital diseases
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Genetics
medicine
lcsh:QH573-671
Gene
Survival analysis
030304 developmental biology
0303 health sciences
Messenger RNA
urogenital system
lcsh:Cytology
Small molecular drugs
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
ADCY3
medicine.disease
nervous system diseases
Oncology
030220 oncology & carcinogenesis
Differentially expressed genes
Cancer research
Primary Research
Glioblastoma
Hub genes
Subjects
Details
- ISSN :
- 14752867
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Cancer Cell International
- Accession number :
- edsair.doi.dedup.....97dbde18830e637c432c58c7aa8d0a5a
- Full Text :
- https://doi.org/10.1186/s12935-020-01515-1